201 related articles for article (PubMed ID: 34304441)
1. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
[No Abstract] [Full Text] [Related]
2. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Diao B; Yang P
Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
[TBL] [Abstract][Full Text] [Related]
3. KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
Zhu S; Bao H; Zhang MC; Liu H; Wang Y; Lin C; Zhao X; Liu SL
BMC Cancer; 2022 Jun; 22(1):662. PubMed ID: 35710397
[TBL] [Abstract][Full Text] [Related]
4. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
6. Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.
Yin F; Yi S; Wei L; Zhao B; Li J; Cai X; Dong C; Liu X
J Cell Biochem; 2019 Apr; 120(4):6057-6070. PubMed ID: 30335894
[TBL] [Abstract][Full Text] [Related]
7. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
9. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract][Full Text] [Related]
10. Increased Expression of
Zou R; Xu H; Li F; Wang S; Zhu L
DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
[TBL] [Abstract][Full Text] [Related]
11. Cancer-testis antigen ACRBP expression and serum immunoreactivity in ovarian cancer: Its association with prognosis.
Lin L; Nong W; Luo B; Ge Y; Zeng X; Li F; Fan R; Zhang Q; Xie X
Immun Inflamm Dis; 2021 Dec; 9(4):1759-1770. PubMed ID: 34528758
[TBL] [Abstract][Full Text] [Related]
12. ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.
Hou L; Zhang X; Jiao Y; Li Y; Zhao Y; Guan Y; Liu Z
Medicine (Baltimore); 2019 May; 98(19):e15698. PubMed ID: 31083274
[TBL] [Abstract][Full Text] [Related]
13. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
[TBL] [Abstract][Full Text] [Related]
14. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.
Gou R; Zhu L; Zheng M; Guo Q; Hu Y; Li X; Liu J; Lin B
J Transl Med; 2019 Sep; 17(1):275. PubMed ID: 31474227
[TBL] [Abstract][Full Text] [Related]
15. REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.
Jia W; Chang B; Sun L; Zhu H; Pang L; Tao L; Zou H; Du J; Dong Y; Qi Y; Jiang J; Liang W; Li F; Zhao X
Int J Clin Exp Pathol; 2014; 7(9):5940-9. PubMed ID: 25337238
[TBL] [Abstract][Full Text] [Related]
16. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
17. Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer.
Lu W; Xie B; Tan G; Dai W; Ren J; Pervaz S; Li K; Li F; Wang Y; Wang M
Front Endocrinol (Lausanne); 2023; 14():1088944. PubMed ID: 36742380
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
Duan C; Li K; Pan X; Wei Z; Xiao L
BMC Cancer; 2023 May; 23(1):489. PubMed ID: 37259027
[TBL] [Abstract][Full Text] [Related]
19. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
20. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.
Yuan L; Bing Z; Yan P; Li R; Wang C; Sun X; Yang J; Shi X; Zhang Y; Yang K
Gene; 2019 Oct; 716():144025. PubMed ID: 31394177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
